DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/86e779/the_outlook_for_ph) has announced the addition of the "The Outlook for Pharmaceuticals in North East Asia" report to their offering.
Detailed analysis of four pharmaceutical markets which present immense potential for pharmaceutical manufacturers. China and Japan will be the largest and second largest pharmaceutical markets in the Asia Pacific region covered by Espicom in 2016.
Diverse Markets, Diverse Opportunities
Geographically located in North East Asia, these four countries are currently undergoing different phases of development, both in overall terms and, more pertinently, in the growth of their respective pharmaceutical markets.
Japan, South Korea and Taiwan represent highly developed pharmaceutical markets with advanced healthcare systems and high levels of spending, both in the private and public sectors. This has inevitably placed a strain on their respective governments which have in recent years tried to temper escalating spending by introducing various cost containment strategies, including periodical changes to reimbursement prices and the encouragement of generic substitution.
Despite these measures, spending has continued to rise. Key factors are the ageing population and the high healthcare standards that the population has grown to expect. While governments hope to control healthcare costs, the trend suggests health spending will continue to rise in the long run.
China's Big Opportunity
China's healthcare provision is somewhat lacking when compared to the other three countries, but it remains one of the fastest growing pharmaceutical markets in the world, in tandem with the country's rapid economic expansion. The influx of foreign multinationals has offered continued investment, and production plants and R&D facilities are being expanded all the time. Improvements in regulatory practices are making the ability to sell imported products quicker and easier, while the lowering of tariffs on imported goods and an increase in transparency of legislation has made a notoriously hard-to-penetrate market a more attractive proposition for overseas companies. These are positive moves, but concerns remain in key areas such as IP protection.
Key Topics Covered:
Highly-detailed analysis providing comprehensive quarterly-updated reports for leading markets in the region:
- China
- Japan
- South Korea
- Taiwan
Executive Summary
Macroenvironment
Epidemiology
Healthcare
Regulatory Affairs
Pricing & Reimbursement
Distribution Channels
Market Analysis
Competition
OTC Pharmaceuticals
Generic Pharmaceuticals
Biologics & Biosimilars
Opportunities & Challenges
Directory
Healthcare Data - Updated Annually
For more information visit http://www.researchandmarkets.com/research/86e779/the_outlook_for_ph
Source: Espicom Business Intelligence Ltd